Invitae's real-world ciitizen data utilized in praxis precision medicines' prax-222 ind filing

– first use of ciitizen platform as source of real-world data in regulatory filing –    san francisco and boston , sept. 20, 2022 /prnewswire/ -- invitae (nyse: nvta) and praxis precision medicines, inc. (nasdaq: prax), today announced that real-world clinical insights from invitae's ciitizen platform were utilized as natural history data to support the submission of praxis' investigational new drug (ind) application for prax-222 for the treatment of pediatric patients with early-onset scn2a developmental and epileptic encephalopathy (dee).
PRAX Ratings Summary
PRAX Quant Ranking